Alnylam Pharmaceuticals — Deal History & Benchmarks
Market Analysis
Alnylam Pharmaceuticals has been involved in 4 transactions totaling $8.1B across Immunology & Autoimmune, Rare Disease, Cardiovascular. As both a licensor and licensee, they have demonstrated a preference for licensing partnerships.
Key transactions include Roche ($2.8B, 2023), Roche ($2.5B, 2024), Regeneron ($1.4B, 2024).
Their deal activity is concentrated in Cardiovascular (50%) with RNAi assets representing their most common deal type.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How many deals has Alnylam Pharmaceuticals done?
What is Alnylam Pharmaceuticals's typical deal structure?
What therapeutic areas does Alnylam Pharmaceuticals focus on?
How has Alnylam Pharmaceuticals's deal activity trended over time?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.